• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca PLC - American Depositary Shares (NQ:AZN)

    82.14 -0.47 (-0.57%)
    Streaming Delayed Price Updated: 3:48 PM EDT, Oct 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,988,042
    Open 83.39
    Bid (Size) 82.13 (4)
    Ask (Size) 82.14 (1)
    Prev. Close 82.61
    Today's Range 81.64 - 83.46
    52wk Range 61.24 - 86.57
    Shares Outstanding N/A
    Dividend Yield 1.25%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
    Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,... 
    Via MarketMinute
    Topics Government World Trade
    3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
    Via MarketBeat

    Performance

    YTD
    +24.7%
    +24.7%
    1 Month
    +10.8%
    +10.8%
    3 Month
    +11.0%
    +11.0%
    6 Month
    +14.5%
    +14.5%
    1 Year
    +8.1%
    +8.1%

    More News

    Read More
    Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
    Via Benzinga
    Topics Initial Public Offering
    Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
    Via MarketMinute
    Danaher Corporation Poised for Growth as Q3 2025 Earnings Spark Optimism
    Via MarketMinute
    Peering Into AstraZeneca PLC's Recent Short Interest
    Via Benzinga
    AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer
    Via Stocktwits
    DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
    From AstraZeneca
    Via Business Wire
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
    From AstraZeneca
    Via Business Wire
    AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
    Via Investor's Business Daily
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
    From AstraZeneca
    Via Business Wire
    TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
    From AstraZeneca
    Via Business Wire
    Invo Fertility Stock Is Plunging After White House Announcement
    Via Benzinga
    IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
    From AstraZeneca
    Via Business Wire
    IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
    From AstraZeneca
    Via Business Wire
    UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
    Via Benzinga
    Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
    Via Benzinga
    2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
    Via The Motley Fool
    Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
    Via Benzinga
    AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug
    Via Stocktwits
    AstraZeneca unveils expanded manufacturing facility in Texas
    From AstraZeneca
    Via Business Wire
    AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment
    Via Chartmill
    Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
    Via Benzinga
    Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
    Via MarketMinute
    Topics Artificial Intelligence
    AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
    From AstraZeneca
    Via Business Wire

    Frequently Asked Questions

    Is AstraZeneca PLC - American Depositary Shares publicly traded?
    Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
    What exchange does AstraZeneca PLC - American Depositary Shares trade on?
    AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
    The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
    What is the current price of AstraZeneca PLC - American Depositary Shares?
    The current price of AstraZeneca PLC - American Depositary Shares is 82.14
    When was AstraZeneca PLC - American Depositary Shares last traded?
    The last trade of AstraZeneca PLC - American Depositary Shares was at 10/29/25 03:48 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.